Applied Molecular Transport Inc. (AMTI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Applied Molecular Transport Inc. (AMTI) trades at $0.26 with AI Score 45/100 (Grade C). Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company focused on developing oral and respiratory biologics. Market cap: $11.01M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for AMTI: AMTI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMTI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AMTI: the 1 perspectives are evenly split.
How is this calculated? →Applied Molecular Transport Inc. (AMTI) Healthcare & Pipeline Overview
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company specializing in oral and respiratory biologics for autoimmune, inflammatory, and metabolic diseases. Their innovative technology platform aims to deliver targeted therapies, with a primary focus on AMT-101, currently in Phase II trials for ulcerative colitis, positioning them in a competitive biotech landscape.
What Is the Investment Thesis for AMTI?
Applied Molecular Transport Inc. presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The primary value driver is the successful development and commercialization of AMT-101, currently in Phase II trials for ulcerative colitis. Positive trial results could lead to significant stock appreciation. The company's innovative oral biologic platform offers potential for pipeline expansion and strategic partnerships. However, the company's small market cap of $11.01M and limited cash reserves introduce substantial financial risk. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure additional funding to sustain operations beyond 2026.
Based on FMP financials and quantitative analysis
AMTI Key Highlights
- AMT-101 is in Phase II clinical trials for the treatment of ulcerative colitis, representing a key milestone in the company's clinical development program.
- AMT-126, a GI-selective oral fusion of interleukin 22, is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects, expanding the company's pipeline.
- The company's technology platform designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics, showcasing innovation.
- The company was founded in 2010 and is headquartered in South San Francisco, California, indicating its presence in a major biotechnology hub.
- The company has a market capitalization of $11.01M, reflecting its small size and potential for high growth or significant risk.
Who Are AMTI's Competitors?
AMTI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABBV AbbVie Inc. | $255.67 | -2.07% | $451.72B | 78 |
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| BMY Bristol-Myers Squibb Company | $56.70 | -2.46% | 116B | 88 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMTI's Key Strengths?
- Innovative oral biologic delivery platform.
- Pipeline of product candidates targeting unmet needs.
- Experienced management team.
- Focus on convenient oral administration.
What Are AMTI's Weaknesses?
- Limited financial resources.
- Reliance on successful clinical trial outcomes.
- Small market capitalization.
- Early-stage development pipeline.
What Could Drive AMTI Stock Higher?
- Announcement of Phase II clinical trial results for AMT-101 in ulcerative colitis (expected in late 2026).
- Initiation of Phase II clinical trials for AMT-101 in additional indications (expected in early 2027).
- Progress of AMT-126 through Phase I clinical trials.
- Potential for strategic partnerships or collaborations with larger pharmaceutical companies.
What Are the Key Risks for AMTI?
- Financial-distress signal — its Altman Z-Score of -39.20 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $1.3M recently.
- Failure of AMT-101 in Phase II clinical trials.
- Regulatory delays or rejection of AMT-101 by the FDA.
- Competition from established pharmaceutical companies with approved therapies.
- Difficulty securing additional funding to support clinical development.
- Intellectual property challenges or patent infringement claims.
What Are the Growth Opportunities for AMTI?
- Expansion of AMT-101 into additional indications: Beyond ulcerative colitis, AMT-101 could be explored for other inflammatory bowel diseases (IBD) such as Crohn's disease. The global IBD market is projected to reach $20 billion by 2028, offering a substantial growth opportunity. Successful clinical trials in these additional indications could significantly increase AMT-101's market potential and extend AMTI's revenue streams.
- Advancement of AMT-126 and other pipeline candidates: Progressing AMT-126 through clinical trials and expanding the pipeline with new oral biologic candidates targeting different diseases represents a key growth driver. Each successful clinical trial outcome increases the company's valuation and attracts potential partnerships. The timeline for these developments depends on clinical trial timelines and regulatory approvals.
- Strategic partnerships and collaborations: Partnering with larger pharmaceutical companies for late-stage development and commercialization of AMT-101 or other pipeline assets can provide significant financial resources and expertise. Such partnerships can accelerate the development process and expand the market reach of AMTI's products. The timing and terms of these partnerships are uncertain but crucial for long-term growth.
- Development of respiratory biologics: Leveraging the company's technology platform to develop respiratory biologics for diseases like asthma and chronic obstructive pulmonary disease (COPD) represents another growth avenue. The respiratory disease market is substantial, with a global value exceeding $40 billion. Success in this area would diversify AMTI's product portfolio and reduce reliance on GI-focused therapies.
- Geographic expansion: Initially focusing on the US market, AMTI can expand its commercial operations to Europe and Asia upon regulatory approval of its products. These regions represent significant market opportunities for autoimmune and inflammatory disease treatments. The timeline for geographic expansion depends on regulatory approvals and the establishment of distribution networks.
What Opportunities Does AMTI Have?
- Expansion into new therapeutic areas.
- Strategic partnerships with larger pharmaceutical companies.
- Positive clinical trial results leading to regulatory approval.
- Growing market for oral biologics.
What Threats Does AMTI Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Difficulty securing additional funding.
What Are AMTI's Competitive Advantages?
- Proprietary oral biologic delivery platform.
- Pipeline of novel product candidates targeting unmet medical needs.
- Intellectual property protection through patents.
- Expertise in developing and manufacturing oral biologics.
What Does AMTI Do?
Founded in 2010 and headquartered in South San Francisco, California, Applied Molecular Transport Inc. (AMTI) is a clinical-stage biopharmaceutical company dedicated to designing and developing a pipeline of oral and respiratory biologic product candidates. These candidates are intended to treat a range of autoimmune, inflammatory, metabolic, and other diseases. The company's core technology platform enables the creation of oral biologic therapeutic modalities, including peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. AMTI's lead product candidate, AMT-101, is a gastrointestinal (GI) selective oral fusion of recombinant human interleukin-10 (rhIL-10). AMT-101 is currently undergoing a Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. Another key product in their pipeline is AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial targeting diseases related to intestinal epithelium barrier function defects. AMTI's strategic focus on oral biologics aims to provide more convenient and effective treatments for patients, differentiating them from traditional injectable biologics.
What Products and Services Does AMTI Offer?
- Develop oral biologic product candidates for autoimmune diseases.
- Design respiratory biologic product candidates for inflammatory diseases.
- Focus on treating metabolic diseases with innovative biologic therapies.
- Utilize a proprietary technology platform for targeted drug delivery.
- Conduct Phase I and Phase II clinical trials to evaluate drug efficacy.
- Develop therapies using peptides, proteins, antibodies, and RNA therapeutics.
How Does AMTI Make Money?
- Develop and patent novel oral and respiratory biologic therapies.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Potentially partner with larger pharmaceutical companies for commercialization.
What Industry Does AMTI Operate In?
Applied Molecular Transport Inc. operates within the highly competitive biotechnology industry, characterized by intense research and development, lengthy regulatory approval processes, and significant capital requirements. The market for oral biologics is growing, driven by patient preference for convenient administration and improved drug delivery. AMTI competes with larger pharmaceutical companies and specialized biotech firms developing treatments for autoimmune and inflammatory diseases. Success in this landscape requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships to navigate the complex regulatory and commercial environment.
Who Are AMTI's Key Customers?
- Patients suffering from ulcerative colitis.
- Patients with other autoimmune and inflammatory diseases.
- Healthcare providers prescribing treatments for these conditions.
- Pharmaceutical companies potentially licensing or acquiring AMTI's therapies.
Net sellingInsider Activity
The most recent 12 insider filings for Applied Molecular Transport Inc. break down as 12 sales and 0 purchases. On net that is roughly 8.7M shares disposed (about $1.3M), a signal worth weighing alongside the fundamentals.
AMTI Valuation & Market Position
With a $11.01M market cap, Applied Molecular Transport Inc. sits in the micro-cap segment of the market. Relative to its peer group, AMTI's quantitative score of 45/100 is below the peer average of 83/100.
F-Score 2/9Financial Health
Applied Molecular Transport Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.20 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Applied Molecular Transport Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Shawn M. Cross. AMTI has traded publicly since 2020.
AMTI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see long-term value, a classic bullish signal.
- Positive community sentiment indicates growing belief in AMTI's pipeline and potential.
- The market seems to be warming up to biotech companies with novel delivery platforms, which could benefit AMTI.
- AMTI's focus on oral biologics delivery addresses a significant unmet need, attracting investor interest.
Bear Case
- Increased short interest suggests skepticism about AMTI's ability to deliver on its clinical trial promises.
- Negative community chatter reflects concerns about potential delays in AMTI's clinical programs.
- The overall market perception of biotech is currently risk-off, impacting smaller players like AMTI more severely.
- Competition in the biologics space is fierce, and AMTI faces challenges in differentiating its technology.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AMTI Latest News
No recent news available for AMTI.
AMTI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMTI.
Price Targets
Wall Street price target analysis for AMTI.
AMTI MoonshotScore
What does this score mean?
The MoonshotScore rates AMTI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shawn M. Cross
Chief Executive Officer
Shawn M. Cross serves as the Chief Executive Officer of Applied Molecular Transport Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and financial management. He has held leadership positions at various biotech companies, contributing to successful product launches and strategic partnerships. Cross's expertise spans across multiple therapeutic areas, including autoimmune diseases and oncology. He is responsible for overseeing the company's overall strategy, clinical development programs, and financial performance.
Track Record: Since joining Applied Molecular Transport Inc., Shawn M. Cross has focused on advancing the company's lead product candidate, AMT-101, through Phase II clinical trials. He has also overseen the expansion of the company's pipeline and the development of its oral biologic delivery platform. Under his leadership, the company has secured key partnerships and collaborations to support its research and development efforts. His strategic decisions have been instrumental in positioning the company for future growth.
What Investors Ask About Applied Molecular Transport Inc. (AMTI) — Healthcare
What does Applied Molecular Transport Inc. do?
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company that specializes in the development of oral and respiratory biologics. Their primary focus is on creating therapies for autoimmune, inflammatory, and metabolic diseases. The company's innovative technology platform allows them to design and develop oral versions of biologic drugs, which are typically administered via injection. Their lead product candidate, AMT-101, is currently in Phase II clinical trials for the treatment of ulcerative colitis, aiming to provide a more convenient and patient-friendly alternative to existing treatments.
What do analysts say about AMTI stock?
Analyst coverage of Applied Molecular Transport Inc. is limited, reflecting its small market capitalization and early-stage development pipeline. Existing analysts generally focus on the potential of AMT-101 and the company's oral biologic delivery platform. Key valuation metrics include the potential market size for ulcerative colitis treatments and the likelihood of successful clinical trial outcomes. Growth considerations revolve around the company's ability to secure additional funding and advance its pipeline through clinical development. Analyst ratings and price targets vary, reflecting the inherent uncertainty associated with clinical-stage biotech companies. No buy or sell recommendations are made.
What are the main risks for AMTI?
The main risks for Applied Molecular Transport Inc. are typical of a clinical-stage biopharmaceutical company. These include the risk of clinical trial failures, particularly for AMT-101, which is the company's lead product candidate. Regulatory hurdles and potential delays in obtaining FDA approval also pose significant risks. Competition from larger pharmaceutical companies with established therapies represents another challenge. Furthermore, the company's limited financial resources and reliance on securing additional funding to support its clinical development programs create financial risk. Intellectual property challenges and potential patent infringement claims could also negatively impact the company's prospects.
What are the key factors to evaluate for AMTI?
Applied Molecular Transport Inc. (AMTI) holds an AI score of 45/100 (low). Not financial advice.
How frequently does AMTI data refresh on this page?
AMTI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AMTI's recent stock price performance?
Applied Molecular Transport Inc. (AMTI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative oral biologic delivery platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AMTI overvalued or undervalued right now?
Valuing Applied Molecular Transport Inc. (AMTI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AMTI?
Before investing in Applied Molecular Transport Inc. (AMTI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is based on limited information due to the company's small size and limited analyst coverage.
- Clinical trial outcomes are inherently uncertain and can significantly impact the company's valuation.